10X Genomics, Inc.

Is 10X Genomics, Inc. technically bullish or bearish?

As of October 10, 2025, 10X Genomics, Inc. shows a mildly bearish trend with key indicators confirming a negative outlook, despite a slightly bullish daily moving average, and has underperformed the S&P 500 significantly year-to-date and over the past year.

As of 10 October 2025, the technical trend for 10X Genomics, Inc. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators such as the weekly MACD and Dow Theory both indicating a mildly bearish position. The Bollinger Bands also confirm a bearish outlook on both weekly and monthly time frames. Although the daily moving averages show a mildly bullish signal, the overall sentiment remains negative due to the prevailing bearish indicators. <BR><BR>In terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -19.22% compared to the S&P 500's 11.41%, and a one-year return of -28.66% versus 13.36% for the index.

How big is 10X Genomics, Inc.?

As of Jun 18, 10X Genomics, Inc. has a market capitalization of 1,318.41 million, with net sales of 624.65 million and a net profit of -157.04 million over the latest four quarters.

Market Cap: As of Jun 18, 10X Genomics, Inc. has a market capitalization of 1,318.41 million, classifying it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, 10X Genomics, Inc. reported net sales of 624.65 million and a net profit of -157.04 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 710.13 million and total assets of 918.64 million.

What does 10X Genomics, Inc. do?

10X Genomics, Inc. is a life science technology company specializing in integrated solutions for biological analysis, with a recent net sales of $155 million and a market cap of $1.32 billion. The company reported a net loss of $34 million as of March 2025.

Overview: <BR>10X Genomics, Inc. is a life science technology company that provides integrated solutions for analyzing biological systems, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 155 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -34 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,318.41 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.59 <BR>Return on Equity: -23.47% <BR>Price to Book: 1.87<BR><BR>Contact Details: <BR>Address: 6230 Stoneridge Mall Road, PLEASANTON CA: 94588 <BR>Tel: 1 925 4017300 <BR>Fax: 1 302 6745266 <BR>Website: https://www.10xgenomics.com/

Should I buy, sell or hold 10X Genomics, Inc.?

Who are in the management team of 10X Genomics, Inc.?

As of March 2022, the management team of 10X Genomics, Inc. includes Mr. John Stuelpnagel (Independent Chairman), Dr. Benjamin Hindson (President, Co-Founder, Chief Scientific Officer), Mr. Serge Saxonov (CEO, Co-Founder), and several independent directors, ensuring a diverse governance structure.

As of March 2022, the management team of 10X Genomics, Inc. includes the following individuals:<BR><BR>- Mr. John Stuelpnagel: Independent Chairman of the Board<BR>- Dr. Benjamin Hindson: President, Co-Founder, Chief Scientific Officer, Director<BR>- Mr. Serge Saxonov: Chief Executive Officer, Co-Founder, Director<BR>- Mr. Sridhar Kosaraju: Independent Director<BR>- Dr. Mathai Mammen: Independent Director<BR>- Ms. Kimberly Popovits: Independent Director<BR>- Dr. Bryan Roberts: Independent Director<BR>- Dr. Shehnaaz Suliman: Independent Director<BR><BR>This team comprises a mix of leadership roles and independent directors, reflecting a diverse governance structure.